Survival with Osimertinib plus Chemotherapy in
Summary
In a phase 3, international, open-label trial (n=557), adding platinum–pemetrexed chemotherapy to first-line osimertinib improved median overall survival from 37.6 to 47.5 months (HR 0.77; P=0.02) in EGFR-mutated NSCLC. Toxicity increased, with grade ≥3 adverse events in 70% vs 34%.
Key Findings
- Median overall survival improved to 47.5 months with osimertinib plus platinum–pemetrexed versus 37.6 months with osimertinib alone.
- Hazard ratio for death was 0.77 (95% CI 0.61–0.96; P=0.02).
- Grade ≥3 adverse events occurred in 70% with combination versus 34% with monotherapy; discontinuation of osimertinib in 12% vs 7%.
Clinical Implications
For appropriate patients, consider osimertinib plus platinum–pemetrexed as a first-line option, balancing a meaningful OS gain against higher toxicity and the need for supportive care.
Why It Matters
This is definitive phase 3 evidence of an overall survival benefit with a new first-line strategy for EGFR-mutated NSCLC, likely to influence treatment guidelines.
Limitations
- Open-label design could introduce bias in some secondary endpoints
- Higher toxicity burden may limit applicability in frail patients
Future Directions
Assess optimal sequencing and duration, biomarker-driven selection for combination therapy, and comparative effectiveness versus modern chemoimmunotherapy backbones.
Study Information
- Study Type
- RCT
- Research Domain
- Treatment
- Evidence Level
- I - Randomized phase 3 trial demonstrating overall survival benefit
- Study Design
- OTHER